In recent years, significant progress has been made in the use of immunotherapy in cancer treatment, especially the use of immune checkpoint inhibitors (anti-PD-1/PD-L1 antibodies), which have been shown to exhibit promising efficacy in the treatment of a wide range of cancers [7]. This evidence concerns the gene CD274 and cancer.